Concepedia

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Y. Chen, S. Yang, Jiawei Shi,

Annals of Oncology · 2019 · 476 citations · 14 references

Open access

References

14

Cancer statistics in China, 2015

Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text

Medicine, Oncology, Population Health Sciences +17

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations

Medicine, Immunology, Oncology +17

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.4K citations · Full text

Medicine, Cancer Biology, Oncology +14

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +12